Age-Related Macular Degeneration (ARMD) Completed Phase 1 / 2 Trials for Ranibizumab (DB01270)

Also known as: Age-related macular degeneration / Macular Degeneration / Senile macular degeneration / Macular degeneration senile / Macular degeneration (senile) of retina, unspecified

IndicationStatusPhase
DBCOND0034150 (Age-Related Macular Degeneration (ARMD))Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02302989Prophylactic Ranibizumab for Exudative Age-Related Macular DegenerationPrevention
NCT02118831Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGFBasic Science
NCT0117539520089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)Treatment